# Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Before completing this template, be sure to register with the pCODR program.

Name of registered clinician: Dr. Andrea Eisen

Name of drug and indication under review: CFulvestrant/locally advanced or metastatic breast cancer

CADTH

**PCODR** PAN-CANADIAN ONCOLOGY DRUG REVIEW

**Conflict of Interest Declarations** 

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

# Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
□ Yes
□ Yes

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - □ Conference attendance
  - Royalties
  - □ Gifts
  - Honoraria
  - Other, please specify: Click here to enter text.

# 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

Click here to enter text.



#### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

#### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:	Clifk holayo esiter lett.
Name:	Click here Apathinteen Esn
Signature:	Click here to Alite



# pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Orit Freedman

Name of drug and indication under review:

# **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

# Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
□ Yes
☑ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - Conference attendance
  - Royalties
  - □ Gifts
  - Honoraria
  - Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

Click here to enter text.



### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

# Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Mar16/17

Name: Orit Freedman

Signature: Click-here to enter text.

# CADTH **FCODR** PAN-CANADIAN ONCOLOGY DRUG REVIEW

Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

# pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Click here to enter text. Daniela Gallo- Herhberg

Name of drug and indication under review: Click here to enter text. Fulvestant - advanced line tastahc Gonflict of Interact Declaration

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

#### Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? X Yes No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards,  $\boxtimes$ HTA submission advice)

Conference attendance

- Program or Operating Funding (e.g., website)
- Research/educational grants
- Travel grants
- Sponsorship of Events

Gifts Honoraria

Rovalties

- Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

**Boehringer Ingelheim** Astellas

# CADTH pCOL

PAN-CANADIAN ONCOLOGY DRUG REVIEW

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

#### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: July 13, 2017

Name: Daniela Gallo-Hershberg

Signature:

Click here to enter text S



# pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Click here to enter text. SHALLENDRA VERNA

Name of drug and indication under review: Click here to enter text. FULVES TEANS

# Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

# Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? **□**∕No

If no, please go to Section B.

Conference attendance

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, Program or Operating Funding Π HTA submission advice) (e.g., website)
    - Research/educational grants
  - Travel grants Royalties Sponsorship of Events Gifts Honoraria NIL
  - Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text.



### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

# NIL

# Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

# JUIL.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:	Click here to enter text. July 19, 2017 Click here to enter text. Stran work VEarnt
Signature:	Click here to enter text. Sharleda D